The biggest-ever study of genetic and observational data now suggests no safe level of alcohol when it comes to dementia risk. Could even “light drinking” be harmful?
IMAGINE THIS: Instead of going to an infusion center for treatment, you can switch to a weekly injection at home. That’s now a reality for many Alzheimer’s patients.
Simple, low-cost lifestyle changes can significantly slow or prevent cognitive decline. New research offers hope for families, caregivers, and anyone invested in brain health.
Women face a higher risk of Alzheimer’s. New research shows that low omega-3 levels may be a hidden factor—and boosting intake through diet or supplements could offer protection.
Caring for someone with Alzheimer’s is demanding enough. Now, instead of traveling for hours of infusions, families can turn to Leqembi IQLIK—a once-weekly injection approved by the FDA that makes treatment simpler, safer, and closer to home.
So many people wait years for a dementia diagnosis—long after symptoms begin. Why? And what can we do about it now?
Trontinemab, an experimental drug developed by Roche, has sparked excitement in large trials for slowing Alzheimer's faster and safer than anything before.
Leqembi, the first Alzheimer's-modifying drug, is a giant step forward—but how many people are getting it, and what does it really cost the average American? We dig into the numbers, the barriers, and the path forward.
Does pain relief risk cognitive cost? A major new study of almost 200,000 people says yes—and the price may be higher than we thought.
Why Do Babies Have More Alzheimer’s Protein Than Adults? A Surprising Clue to Future Treatments
Diagnosing the right dementia type often takes months. It can make a big difference. Mayo Clinic’s AI tool identifies 9 dementia types, including Alzheimer’s, with one scan — a transformative advance in early, accurate diagnosis.
Bill Gates says, "I am blown away by how much we have learned about Alzheimer’s disease over the last couple years." See his compelling video and insight-filled blog post.